June 19, 2014.
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, and Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Nicox’s subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories’ RetnaGene™ portfolio of laboratory-developed genetic tests in the United States (U.S.). The RetnaGene portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests, which assess an individual’s risk for advanced age-related macular degeneration (AMD).
Nicox is headquartered in Sophia Antipolis (Nice, France) and is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX). North American operations are based in Fort Worth (Texas, United States) and research capabilities in Bresso (Milan, Italy).
18 years of experience in pharmaceutical R&D
253 patents granted
150 employees worldwide
6 sales operations offices: UK, France, Italy, Spain, Germany and USA
2012 is the year when Nicox became a specialized ophthalmic company